Skip to main content

Table 1 Patient characteristics

From: Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma

Patient characteristics

HCC

non-HCC malignancies

non-HCC benign lesions

No. of patients

165

30

16

No. of lesions

173

32

24

Sex (male)

133 (80.6%)

24 (80.0%)

12 (75.0%)

Age (years, mean [range])

51.2 (26–83)

53.6 (39–77)

49.1 (30–60)

Size (cm, mean ± SD)

5.74 ± 3.17

5.64 ± 2.36

2.93 ± 2.43

Interval between MR imaging and surgery (d, mean ± SD)

2.73 ± 1.99

2.81 ± 2.25

4.62 ± 7.13

Underlying Diseases

 HBV-related cirrhosis

108

10

6

 HBV carrier (not cirrhotic)

52

16

9

 Cirrhosis of other causes

5

4

1

Child-Pugh Class

 A

164 (99.4%)

27 (90.0%)

16 (100.0%)

 B

1 (0.6%)

3 (10.0%)

0

ALT (IU/L)

 >40

68 (41.2%)

6 (20.0%)

2 (12.5%)

AST (IU/L)

 >35

84 (50.9%)

7 (23.3%)

1 (6.3%)

TBIL (umol/L)

 >28.0

11 (6.7%)

4 (13.3%)

1 (6.3%)

IBIL (umol/L)

 >20.0

6 (3.6%)

5 (16.7%)

1 (6.3%)

ALB (g/L)

 <35

4 (2.4%)

2 (6.7%)

0

PT (s)

 >12.8

42 (25.5%)

4 (13.3%)

0

PLT (×10^9/L)

 <100

30 (18.2%)

3 (10.0%)

2 (12.5%)

HBsAg (COI)

 >10

105 (84.8%)

12 (40.0%)

9 (56.3%)

AFP (ng/ml)

 >20

105 (63.6%)

10 (33.3%)

1 (6.3%)

CEA (ng/ml)

 >3.4

29 (17.6%)

11 (36.7%)

1 (6.3%)

CA 19–9 (U/ml)

 >22

68 (41.2%)

15 (50.0%)

0

  1. Abbreviations: HCC hepatocellular carcinoma, SD standard deviation, MR magnetic resonance, CT computed tomography, HBV hepatitis B virus, NAFLD non-alcoholic fatty liver disease, ALT alanine aminotransferase, AST aspartate aminotransferase, TBIL total bilirubin, IBIL indirect bilirubin, ALB albumin, PT prothrombin time, PLT platelet, HBsAg hepatitis B virus surface antigen, AFP alpha-fetoprotein, CEA carcinoembryonic antigen, CA 19–9 carbohydrate antigen 19–9